Physician profile
David J Ernst
NPI 1639115827
$1,892.46
in general payments reported to CMS, 2019-2025
11 companies · $41.25 in 2025
The $41.25 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $293 · 2021: $345 · 2022: $424 · 2023: $280 · 2024: $361 · 2025: $41.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $689.91 | 2020-2024 | Jakafi |
| Merck Sharp & Dohme LLC | $249.38 | 2019-2024 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $180.92 | 2022-2025 | Tagrisso, Enhertu |
| Eisai INC. | $173.73 | 2021-2024 | |
| Genzyme Corporation | $133.80 | 2023 | |
| Janssen Biotech, INC. | $120.40 | 2019 | |
| Daiichi Sankyo INC. | $117.14 | 2020 | |
| Seagen INC. | $103.25 | 2021 | |
| Glaxosmithkline, LLC. | $60.40 | 2024-2025 | Ojjaara |
| Amgen INC. | $39.49 | 2019-2020 | |
| Sobi, INC | $24.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ernst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.